STATE-OF-THE-ART PAPER
Recent hypertension trials
Implications and controversies
Bryan Williams, MD, FRCP, FAHA*
Department of Cardiovascular Sciences, University of Leicester School of Medicine, Leicester, United Kingdom
Manuscript received September 8, 2004;
revised manuscript received October 16, 2004,
accepted October 18, 2004.
* Reprint requests and correspondence: Dr. Bryan Williams, Professor of Medicine, Clinical Sciences Building, Leicester Royal Infirmary, P.O. Box 65, Leicester LE2 7LX, United Kingdom
(Email: bw17{at}le.ac.uk).
The pharmacologic treatment of hypertension has been extensively studied by clinical trials. These studies have provided definitive evidence of a treatment benefit, and the weight and consistency of the clinical evidence has led to uniformity in many aspects of treatment recommendations worldwide. However, controversies remain—in particular, whether specific classes of drug therapy offer benefits for cardiovascular disease prevention beyond the expected benefits of blood pressure lowering per se. Updated large-scale epidemiologic studies and the meta-analysis of clinical trial data have better informed this debate and emphasized that the main driver of clinical benefit from blood pressure-lowering therapy is the magnitude of blood pressure reduction and perhaps the speed at which it is achieved. However, clinical trials are of short duration, and there are more marked drug-specific differences in intermediate cardiovascular structure, functional, and metabolic end points. The challenge is to interpret their significance with regard to longer term outcomes. Finally, although blood pressure lowering is undoubtedly beneficial, the concepts of single risk factor intervention and arbitrary blood pressure thresholds and treatment goals are being challenged by the recognition that the real target is cardiovascular disease risk. Undoubtedly, the most effective way to "go beyond blood pressure" is to add a statin.
|
Abbreviations and Acronyms
| | ACE = angiotensin-converting enzyme | | AF = atrial fibrillation | | ARB = angiotensin receptor blocker | | CCB = calcium channel blocker | | CHD = coronary heart disease | | CI = confidence interval | | CVD = cardiovascular disease | | HF = heart failure | | MI = myocardial infarction |
|
This article has been cited by other articles:
|
|
|
|
 
C. S. Thompson and A. M. Hakim
Living Beyond Our Physiological Means: Small Vessel Disease of the Brain Is an Expression of a Systemic Failure in Arteriolar Function: A Unifying Hypothesis
Stroke,
May 1, 2009;
40(5):
e322 - e330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Gojanovic, F. Feihl, L. Liaudet, and B. Waeber
Review: Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension
Journal of Renin-Angiotensin-Aldosterone System,
March 1, 2008;
9(1):
1 - 9.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. Jackson
Gender differences in cardiovascular disease prevention
Menopause Int,
March 1, 2008;
14(1):
13 - 17.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Knecht, H. Wersching, H. Lohmann, M. Bruchmann, T. Duning, R. Dziewas, K. Berger, and E. B. Ringelstein
High-Normal Blood Pressure Is Associated With Poor Cognitive Performance
Hypertension,
March 1, 2008;
51(3):
663 - 668.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Ferrario, J. Basile, W. Bestermann, E. Frohlich, M. Houston, D. T. Lackland, R. D. Smith, and D. L. Wise
Review: The role of noninvasive hemodynamic monitoring in the evaluation and treatment of hypertension
Therapeutic Advances in Cardiovascular Disease,
December 1, 2007;
1(2):
113 - 118.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. Williams
Hypertension in the Young: Preventing the Evolution of Disease Versus Prevention of Clinical Events
J. Am. Coll. Cardiol.,
August 28, 2007;
50(9):
840 - 842.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Pfeffer
Blood Pressure in Heart Failure: A Love-Hate Relationship
J. Am. Coll. Cardiol.,
January 2, 2007;
49(1):
40 - 42.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Pfeffer and E. D. Frohlich
Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation
Am J Physiol Heart Circ Physiol,
November 1, 2006;
291(5):
H2021 - H2025.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Ferrario and R. D. Smith
Response to Reduction of Blood Pressure Levels Study Group
Hypertension,
November 1, 2006;
48(5):
e105 - e105.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Smith, P. Levy, C. M. Ferrario, and for the Consideration of Noninvasive Hemodynamic M
Value of Noninvasive Hemodynamics to Achieve Blood Pressure Control in Hypertensive Subjects
Hypertension,
April 1, 2006;
47(4):
771 - 777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial, CAFE Steering Committee and Writing Committee, B. Williams, P. S. Lacy, S. M. Thom, K. Cruickshank, A. Stanton, D. Collier, A. D. Hughes, et al.
Differential Impact of Blood Pressure-Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study
Circulation,
March 7, 2006;
113(9):
1213 - 1225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Pepine, P. R. Kowey, S. Kupfer, R. E. Kolloch, A. Benetos, G. Mancia, A. Coca, R. M. Cooper-DeHoff, E. Handberg, E. Gaxiola, et al.
Predictors of Adverse Outcome Among Patients With Hypertension and Coronary Artery Disease
J. Am. Coll. Cardiol.,
February 7, 2006;
47(3):
547 - 551.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Prepared by: British Cardiac Society, British Hype
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
Heart,
December 1, 2005;
91(suppl_5):
v1 - v52.
[Full Text]
[PDF]
|
|
|
|
